TransDerm, a small biotech focused on developing a treatment for pachyonychia congenita (PC), has just kicked off a phase I trial of a new drug candidate designed to treat the rare skin condition.
Title: Lentiviral Transduced Dendritic Cells for RNAi Patent Number: 8,530,153 Filed: March 10, 2011 Inventor: Sam Kam Pun Kung, University of Manitoba
Researchers from TransDerm, which is developing RNAi-based treatments for skin disorders including pachyonychia congenita, last month published a report on the development of an in vivo imaging approach that can be used to rapidly screen and optimize siRNA delivery techn
TransDerm is preparing to begin the toxicology studies needed to launch a phase I trial of an improved version of its siRNA-based treatment for pachyonychia congenita, or PC, and expects the study to begin next year, Gene Silencing News has learned.
Sep 29, 2011
Jun 17, 2010
Apr 29, 2010
Nov 12, 2009